1-2 of 2 results for subject:Baricitinib
Librarians' tools
- Search time
- 0.204 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Baricitinib
- We searched for
- subject_t:Baricitinib OR subject_t:Olumiant OR subject_ses:522414
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to facilitate access on the NHS to baricitinib for children and young people with juvenile idiopathic arthritis (JIA); and whether he has considered alternative commissioning or funding routes for that treatment in the...
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to facilitate access on the NHS to baricitinib for children and young people with juvenile idiopathic arthritis (JIA); and whether he has considered alternative commissioning or funding routes for that treatment in the...
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based recommendations for the National Health Service on whether new, licensed medicines represent a clinically and cost-effective use of NHS resources. The NHS in England is legally required to fund medicines recommended by NICE.
NICE has unfortunately been unable to develop guidance for the NHS on the use of baricitinib for treating juvenile idiopathic arthritis in people two years old and over because the company, Eli Lilly, did not provide an evidence submission. NICE will review its decision if the company decides to make a new evidence submission.
Decisions on whether to fund medicines in the absence of NICE guidance are for NHS commissioners. NHS England does not fund medicines where the company has not engaged with NICE. This is to avoid a potential pathway for circumventing the NICE appraisal process. NHS England’s policy on non-submission of data to NICE is available at the following link:
To ask the Secretary of State for Health and Social Care, what steps the NHS is taking to fund Baricitinib for the treatment of severe alopecia areata.
To ask the Secretary of State for Health and Social Care, what steps the NHS is taking to fund Baricitinib for the treatment of severe alopecia areata.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing evidence-based guidance for the National Health Service on whether medicines represent a clinically and cost-effective use of resources. The NHS in England is legally required to fund medicines recommended in a NICE appraisal, usually within three months of final guidance.
NICE published final draft guidance on 18 May 2023 which does not recommend baricitinib for the treatment of severe alopecia areata. An appeal has been made against NICE’s final draft guidance by Alopecia UK which will be considered by NICE’s appeal panel on 12 September 2023. NICE will issue final guidance in due course.